Menu
  • Home
  • Donate
    • to Cure Our Ovarian Cancer
    • to Fundraiser
    • Legacy Giving
  • About
    • Cure Our Ovarian Cancer
    • Low Grade Serous Ovarian Cancer
    • Our Charity Partners
    • Ovarian Cancer Symptoms
    • Additional FAQs
  • Our Stories
  • Support
    • For Women & Families
    • Help Fundraise
      • Fundraiser login
    • Become a Regular Giver
    • Share your story
      • Story Login
  • News
  • Contact Us
Teal-Heart-Cure-Our-Ovarian-Cancer-Logo
Menu
  • Home
  • Donate
    • to Cure Our Ovarian Cancer
    • to Fundraiser
    • Legacy Giving
  • About
    • Cure Our Ovarian Cancer
    • Low Grade Serous Ovarian Cancer
    • Our Charity Partners
    • Ovarian Cancer Symptoms
    • Additional FAQs
  • Our Stories
  • Support
    • For Women & Families
    • Help Fundraise
      • Fundraiser login
    • Become a Regular Giver
    • Share your story
      • Story Login
  • News
  • Contact Us
EU-Flag
EU
EU-Flag
Europe
cureourovariancancer.org/eu
Donate Now
Fundraise
Donate Now
Fundraise
  • News / September 30, 2019

    Study Shows Trametinib Improves Outcomes for Women with Low-Grade Serous Carcinoma of the Ovary/Peritoneum on NRG Oncology Trial

    View Post
  • News / August 24, 2018

    Cancer isn’t a war or a battle, but maybe cancer research is

    View Post
  • News / December 3, 2020

    Verastem Oncology investigates new LGSOC treatment

    View Post
  • News / October 10, 2019

    World Hospice and Palliative Care Day

    View Post
  • News / November 27, 2019

    Binimetinib in low-grade serous carcinoma

    View Post
View Post

Verastem Oncology investigates new LGSOC treatment

Biopharmaceutical company Verastem Oncology has announced a new Phase 2 clinical trial for low-grade serous cancer (LGSOC). The trial will …

View Post

Cancer, Covid and Christmas

A Year of Change By Diane Evans-Wood Last year I wrote a blog about how to get through Christmas whilst …

View Post

Coping with cancer at Christmas

It’s November and already that time of year again when the Christmas adverts appear on TV and the shops are …

View Post

Binimetinib in low-grade serous carcinoma

A phase II study of Selumetinib, an oral small-molecule inhibitor of MEK1/2, has shown promising results in patients with recurrent …

View Post

Giving CuresDay on Giving Tuesday

Cure Our Ovarian Cancer is Celebrating GivingTuesday in Europe with #GivingCuresDay joining millions around the world participating in the global …

View Post

World Hospice and Palliative Care Day

On Saturday 12 October, people across the world will be celebrating and supporting hospice and palliative care. As World Hospice …

View Post

Study Shows Trametinib Improves Outcomes for Women with Low-Grade Serous Carcinoma of the Ovary/Peritoneum on NRG Oncology Trial

Results from GOG 0281, a randomised phase II/III clinical trial, were presented by Dr Gershenson on Sunday at the European …

View Post

World Ovarian Cancer Day

What is World Ovarian Cancer Day May 8th is World Ovarian Cancer Day – an initiative of the World Ovarian …

View Post

#OneHellOvaWoman

It is with a very heavy heart that we received the news that Elly Mayday passed away on the 1st …

View Post

The Five Easiest Fundraisers

Have you created a fundraiser yet? Here are five easy ideas to get you started. Use an existing event. For …

  • Page 1 of 2
  • 1
  • 2
  • →
Sign up to our mailing list
Sign up to our mailing list
Privacy Policy

Site Links

Home

Donate
to Cure Our Ovarian Cancer
Fundraiser
Legacy Giving

About
Cure Our Ovarian Cancer
Low Grade Serous Ovarian Cancer
Our Charity Partners
Additional FAQs
Ovarian Cancer Symptoms

Our Stories

Support
Help Fundraise
Fundraiser Login
Become a Regular Giver
Share Your Story
Story Login
Support Groups
Find a Clinical Trial

News

Contact Us

Our Websites
International

Australia
Canada

Europe
New Zealand

United Kingdom
United States

Connect with us:
Privacy Policy

© 2018 Cure Our Ovarian Cancer

View NZ Charity registration: CC55925. We are committed to improving the survival of women everywhere.